Condition: Pneumococcal Infections · Pneumococcal Conjugate Vaccine · Antibiotic Treatment · Sponsor: Association Clinique Thérapeutique Infantile du val de Marne
After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.
This description comes directly from the study's public registry record.
Levy Corinne · 1 48 85 04 04 · corinne.levy@activ-france.fr
Bechet Stephane · 1 48 85 96 68 · stephane.bechet@activ-france.fr
Always discuss trial participation with your own doctor first.
| ACTIV | Créteil, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04664556